Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial–Mesenchymal Transition

SIMPLE SUMMARY: Osimertinib is widely employed in patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). Most EGFR-mutated NSCLC cells are killed within a few days after osimertinib treatment; however, surviving cells remain detectable and are called drug-t...

Descripción completa

Detalles Bibliográficos
Autores principales: Tokumo, Kentaro, Masuda, Takeshi, Nakashima, Taku, Namba, Masashi, Yamaguchi, Kakuhiro, Sakamoto, Shinjiro, Horimasu, Yasushi, Miyamoto, Shintaro, Iwamoto, Hiroshi, Fujitaka, Kazunori, Miyata, Yoshihiro, Okada, Morihito, Hamada, Hironobu, Hattori, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954529/
https://www.ncbi.nlm.nih.gov/pubmed/36831438
http://dx.doi.org/10.3390/cancers15041092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954529/
https://www.ncbi.nlm.nih.gov/pubmed/36831438
http://dx.doi.org/10.3390/cancers15041092

Ejemplares similares